Ultragenyx Pharmaceutical (RARE)
(Delayed Data from NSDQ)
$45.27 USD
+0.81 (1.82%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $45.24 -0.03 (-0.07%) 7:04 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Brokerage Reports
Ultragenyx Pharmaceutical Inc. [RARE]
Reports for Purchase
Showing records 261 - 280 ( 333 total )
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Multiple Value Inflection Points in 2018 from Maturing Rare Disease Pipeline
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Ph 2 UX007 Data Could Support Filing; Upcoming Catalysts Are Undervalued
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Positive Opinion Issued for Burosumab, Shares Look Attractive Ahead of Approval
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Focus on XLH Update and New Pipeline Programs at Analyst Day
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Mepsevii Approved, Pricing comes In-line with Expectations
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Well-Positioned with Two Rare Disease Products on Market in Near-Term
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Bid for DMTX Would Add a Promising (but Early-Stage) Gene Therapy Pipeline
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Upgrading to OUTPERFORM as Valuation Looks Attractive Post-ASBMR
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Reducing Valuation on Ace-ER Discontinuation
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
The KRN23 BLA for Adults and Pediatric XLH Patients Expected in August; New PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: WERTHER C
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Bone Fracture Data is Positive for KRN23 Program, But Challenges Remain with Overall Profile, Reiterate NEUTRAL
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
The Best News May Be Done for Some TIme, Downgrading to Neutral, New PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: WERTHER C
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Downgrading to NEUTRAL and Reducing PT: Adult XLH Results Support KRN23 Approval, but Less Robust Pain Benefit Likely to Slow Uptake
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D